cancer treatment

Autolus to present pipeline updates and 2025 financial results at two March 2026 healthcare conferences, discussing commercial progress and strategic priorities.

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.

Sensei Biotherapeutics stock surged 230% after acquiring Faeth Therapeutics and securing $200M investment, expanding its oncology pipeline with PIKTOR therapy.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.